The SEC is expected to drop an investigation into Illumina’s (ILMN) $8B acquisition of cancer test developer Grail (GRAL), reported Endpoints News’ Jared Whitlock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- ILMN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Illumina, Ovation.io launching first-of-kind GLP-1 dataset
- Illumina price target lowered to $92 from $115 at Canaccord
- BTIG Analyst Sees Tempus AI (TEM) as “Significant Free Call Option” with 48% Upside
- Illumina price target lowered to $90 from $130 at Bernstein